AZD-6370

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H23N3O6S
Molecular Weight	445.489
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](CO)OC1=CC(OC2=CC=C(C=C2)S(C)(=O)=O)=CC(=C1)C(=O)NC3=NN(C)C=C3

InChI

InChIKey=RIIDAVMUCMIWKP-AWEZNQCLSA-N

InChI=1S/C21H23N3O6S/c1-14(13-25)29-17-10-15(21(26)22-20-8-9-24(2)23-20)11-18(12-17)30-16-4-6-19(7-5-16)31(3,27)28/h4-12,14,25H,13H2,1-3H3,(H,22,23,26)/t14-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C21H23N3O6S
Molecular Weight	445.489
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 12:12:56 GMT 2023` Edited by `admin` on `Sat Dec 16 12:12:56 GMT 2023`
Record UNII	Z7H4089VLO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZD-6370

Code

English

BENZAMIDE, 3-((1S)-2-HYDROXY-1-METHYLETHOXY)-N-(1-METHYL-1H-PYRAZOL-3-YL)-5-(4-(METHYLSULFONYL)PHENOXY)-

Systematic Name

English

3-(((1S)-2-HYDROXY-1-METHYLETHYL)OXY)-N-(1-METHYL-1H-PYRAZOL-3-YL)-5-(4-(METHYLSULFONYL)PHENOXY)BENZAMIDE

Systematic Name

English

AZD 6370 [WHO-DD]

Common Name

English

Code System Code Type Description

PUBCHEM

11525116

Created by admin on Sat Dec 16 12:12:56 GMT 2023 , Edited by admin on Sat Dec 16 12:12:56 GMT 2023

PRIMARY

CAS

752239-85-3

Created by admin on Sat Dec 16 12:12:56 GMT 2023 , Edited by admin on Sat Dec 16 12:12:56 GMT 2023

PRIMARY

FDA UNII

Z7H4089VLO

Created by admin on Sat Dec 16 12:12:56 GMT 2023 , Edited by admin on Sat Dec 16 12:12:56 GMT 2023

PRIMARY

Related Record Type Details


					Z7H4089VLO

AZD-6370

ACTIVE MOIETY

Comments:

Class: Antihyperglycaemic, Pyridine; Mechanism of Action: Glucokinase stimulant; Highest Development Phases: Discontinued for Type 2 diabetes mellitus; Most Recent Events: 27 Jan 2011 Discontinued - Phase-II for Type-2 diabetes mellitus in Sweden (PO), 31 Jul 2008 Phase-II clinical trials in Type-2 diabetes mellitus in Sweden (PO), 31 Jul 2007 Phase-I clinical trials in Type-2 diabetes mellitus in Sweden (PO)


					Z7H4089VLO

AZD-6370

ACTIVE MOIETY

Comments:

AZD6370 was well tolerated and no safety concerns were raised. AZD6370 was rapidly absorbed and eliminated, and plasma concentration was proportional to dose. Both S-insulin and GIR increased following AZD6370 administration. The observed increase in GIR correlated with increasing AZD6370 area under the plasma concentration vs. time curve, demonstrating a dose-concentration-dependent pharmacodynamic effect. AZD6370 at doses of 50 and 80 mg had similar effects to short-acting insulin 4 U on peripheral S-insulin levels but greater effects on GIR, suggesting an effect beyond the increase of peripheral S-insulin levels at lower doses.